IDEX’s first quarter results were met with a positive market reaction, as management pointed to substantial growth in Health & Science Technologies (HST) and robust order activity across its core segments. CEO Eric Ashleman credited the quarter’s performance to strong execution in targeted end markets, particularly data center, semiconductor, and space and defense applications. Orders grew organically by 10%, with HST leading at 17%, demonstrating that the company’s recent portfolio shift toward high-value, durable markets is gaining traction. Management also highlighted disciplined cost control and the ongoing deployment of the 8020 strategy, which focuses resources on the most promising customers and applications.
Is now the time to buy IEX? Find out in our full research report (it’s free for active Edge members).
IDEX (IEX) Q1 CY2026 Highlights:
- Revenue: $886.9 million vs analyst estimates of $847.4 million (8.9% year-on-year growth, 4.7% beat)
- Adjusted EPS: $2 vs analyst estimates of $1.77 (12.9% beat)
- Adjusted EBITDA: $230.4 million vs analyst estimates of $210 million (26% margin, 9.7% beat)
- Revenue Guidance for Q2 CY2026 is $895.7 million at the midpoint, above analyst estimates of $888.4 million
- Management raised its full-year Adjusted EPS guidance to $8.45 at the midpoint, a 2.4% increase
- Operating Margin: 19.4%, up from 17.4% in the same quarter last year
- Organic Revenue rose 5% year on year (miss)
- Market Capitalization: $15.97 billion
While we enjoy listening to the management's commentary, our favorite part of earnings calls are the analyst questions. Those are unscripted and can often highlight topics that management teams would rather avoid or topics where the answer is complicated. Here is what has caught our attention.
Our Top 5 Analyst Questions From IDEX’s Q1 Earnings Call
-
Joseph Giordano (TD Cowen) questioned why the second half organic growth guide is more conservative despite strong order trends. CFO Sean Gillen explained, “There’s some macro uncertainty, and we’re keeping a flat outlook for FMT given limited visibility.”
-
Matt Summerville (D.A. Davidson) asked about the outlook for life sciences growth in HST. CEO Eric Ashleman said, “Low single-digit growth is expected, with pharma strong but pressures persisting in China and NIH-funded academic markets.”
-
Nathan Jones (Stifel) probed HST margins and incremental flow-through. Gillen cited acquired businesses operating below segment average and ongoing 8020 actions as key to improving future margins.
-
Deane Dray (RBC) inquired about water platform demand in FMT. Ashleman noted continued strength in municipal applications and a turnaround in high-purity water for semiconductors, expecting both trends to sustain.
-
Robert Wertheimer (Melius Research) asked about the contribution of new markets and acquisitions to order growth. Ashleman stressed that much of the growth is attributable to recently acquired units aligned with advantaged markets and ongoing innovation initiatives.
Catalysts in Upcoming Quarters
Looking ahead, the StockStory team will be monitoring (1) sustained backlog growth and order momentum in HST as a sign of continued demand in advantaged markets, (2) sequential improvement and recovery signs in short-cycle FMT and FSDP businesses, and (3) incremental margin gains from portfolio integration and productivity initiatives. Progress on bolt-on M&A and the ability to navigate macroeconomic uncertainties will also be important indicators.
IDEX currently trades at $215.83, up from $205.36 just before the earnings. At this price, is it a buy or sell? Find out in our full research report (it’s free).
High-Quality Stocks for All Market Conditions
ALSO WORTH WATCHING: Top 5 Momentum Stocks. The best time to own a great stock is when the market is finally noticing it. These aren't just high-quality businesses. Something is happening with them right now. Elite fundamentals meeting near-term momentum - both boxes checked at the same time.
Find out which stocks our AI platform is flagging this week. See this week's Strong Momentum stocks - FREE. Get Our Strong Momentum Stocks for Free HERE.
Stocks that have made our list include now familiar names such as Nvidia (+1,326% between June 2020 and June 2025) as well as under-the-radar businesses like the once-micro-cap company Kadant (+351% five-year return). Find your next big winner with StockStory today.